Affordable Access

deepdyve-link
Publisher Website

Monocyte HLA-DR Measurement by Flow Cytometry in COVID-19 Patients: An Interim Review.

Authors
  • Benlyamani, Ihsane1, 2
  • Venet, Fabienne1, 2
  • Coudereau, Rémy1, 2
  • Gossez, Morgane1, 2
  • Monneret, Guillaume1, 2
  • 1 Laboratoire d'Immunologie, Hôpital E. Herriot, Hospices Civils de Lyon, Lyon, France. , (France)
  • 2 Université de Lyon, Université Claude Bernard Lyon 1, EA7426, Lyon, France. , (France)
Type
Published Article
Journal
Cytometry Part A
Publisher
Wiley (John Wiley & Sons)
Publication Date
Dec 01, 2020
Volume
97
Issue
12
Pages
1217–1221
Identifiers
DOI: 10.1002/cyto.a.24249
PMID: 33125816
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Several months after the sudden emergence of SARS-CoV-2 and COVID-19, the understanding of the appropriate host immune response to a virus totally unknown of human immune surveillance is still of major importance. By international definition, COVID-19 falls in the scope of septic syndromes (organ dysfunction due to dysregulated host response to an infection) in which immunosuppression is a significant driver of mortality. Sepsis-induced immunosuppression is mostly defined and monitored by the measurement of decreased expression of HLA-DR molecules on circulating monocytes (mHLA-DR). In this interim review, we summarize the first mHLA-DR results in COVID-19 patients. In critically ill patients, results homogenously indicate a decreased mHLA-DR expression, which, along with profound lymphopenia and other functional alterations, is indicative of a status of immunosuppression. © 2020 International Society for Advancement of Cytometry. © 2020 International Society for Advancement of Cytometry.

Report this publication

Statistics

Seen <100 times